ArticleJBMR plus2026
Impaired bone matrix maturation and mineralization are prevalent in adolescent end-stage kidney disease.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children and adolescents with end-stage kidney disease (ESKD) have a high prevalence of bone deformities and fractures, even when bone histomorphometric measures of bone formation, mineralization, and volume are within normal range. We postulated that bone matrix quality and osteocyte differentiation are impaired in ESKD in ways which might be not reflected by alterations in surface-based cell activity. We assessed bone turnover, mineralization, and volume by traditional histomorphometry in bone biopsy cores from 24 adolescent patients with ESKD. We stained sequential sections of the same cores for apoptosis (TUNEL staining) and for osteocyte-specific maturation markers (sclerostin, DMP1, and FGF23). We then performed quantitative backscattered electron imaging (qBEI) to assess bone mineralization density distribution on the whole bone surface and additionally in bone packets containing FGF23-expressing osteocytes. Increased amounts of osteoid (OV/BV > 4.7%) and a true defect in bone surface mineralization (O.Th > 10 μm combined with MLT > 27.1 d) were detectable by histomorphometry in 29% and 17% of bone samples, respectively. By contrast, qBEI detected an excess in primary mineralizing bone (TbCaLow > 6.8%) in 88% of samples and abnormally low bone matrix mineralization (TbCaMean < 22.1 wt% calcium) in 75% of samples. Osteocyte lacunar density and size were within normal range. Unexpectedly, higher numbers of FGF23-expressing osteocytes and a more elongated osteocyte lacunar shape were found in bone samples with greater matrix mineralization. In conclusion, matrix mineralization defects, which are not detected by traditional histomorphometry, are highly prevalent in ESKD bone and reflect poor bone matrix maturation. High numbers of FGF23-expressing osteocytes are found in bone with the most appropriate matrix maturation characteristics. This differs from the bone characteristics of individuals with normal kidney function, in whom large amounts of FGF23 result in low circulating phosphate levels, which in turn triggers severe osteomalacia and hypomineralized periosteocytic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.